Prenetics Global (NASDAQ:PRE – Get Free Report) and Singular Genomics Systems (NASDAQ:OMIC – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations and institutional ownership.
Valuation and Earnings
This table compares Prenetics Global and Singular Genomics Systems”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Prenetics Global | $25.56 million | 1.95 | -$62.72 million | ($3.99) | -1.03 |
| Singular Genomics Systems | $2.91 million | 17.47 | -$94.82 million | ($35.11) | -0.57 |
Prenetics Global has higher revenue and earnings than Singular Genomics Systems. Prenetics Global is trading at a lower price-to-earnings ratio than Singular Genomics Systems, indicating that it is currently the more affordable of the two stocks.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Prenetics Global | -191.73% | -16.45% | -13.34% |
| Singular Genomics Systems | -3,237.89% | -57.87% | -37.90% |
Insider and Institutional Ownership
25.0% of Prenetics Global shares are owned by institutional investors. Comparatively, 65.8% of Singular Genomics Systems shares are owned by institutional investors. 7.8% of Prenetics Global shares are owned by company insiders. Comparatively, 22.2% of Singular Genomics Systems shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Volatility and Risk
Prenetics Global has a beta of -0.31, indicating that its stock price is 131% less volatile than the S&P 500. Comparatively, Singular Genomics Systems has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current recommendations for Prenetics Global and Singular Genomics Systems, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Prenetics Global | 0 | 0 | 1 | 0 | 3.00 |
| Singular Genomics Systems | 0 | 1 | 0 | 0 | 2.00 |
Prenetics Global presently has a consensus target price of $9.00, indicating a potential upside of 119.94%. Singular Genomics Systems has a consensus target price of $6.50, indicating a potential downside of 67.52%. Given Prenetics Global’s stronger consensus rating and higher possible upside, equities analysts clearly believe Prenetics Global is more favorable than Singular Genomics Systems.
Summary
Prenetics Global beats Singular Genomics Systems on 9 of the 14 factors compared between the two stocks.
About Prenetics Global
Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.
About Singular Genomics Systems
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue. Singular Genomics Systems, Inc. was incorporated in 2016 and is based in San Diego, California.
Receive News & Ratings for Prenetics Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prenetics Global and related companies with MarketBeat.com's FREE daily email newsletter.
